A5071318362- Prostate Cancer Treatment and Research
- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Multiple and Secondary Primary Cancers
- PARP inhibition in cancer therapy
- COVID-19 and healthcare impacts
- Hormonal and reproductive studies
- Renal cell carcinoma treatment
- Cancer, Lipids, and Metabolism
- Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Colorectal Cancer Treatments and Studies
- Cancer, Stress, Anesthesia, and Immune Response
- Bone health and treatments
- Statistical Methods in Clinical Trials
- COVID-19 Clinical Research Studies
- Bone health and osteoporosis research
- Genital Health and Disease
- SARS-CoV-2 and COVID-19 Research
- Multiple Myeloma Research and Treatments
- Adipose Tissue and Metabolism
- Diet and metabolism studies
Icahn School of Medicine at Mount Sinai
2015-2024
Rutgers, The State University of New Jersey
2024
Rutgers New Jersey Medical School
2024
Arvinas (United States)
2024
Mount Sinai Health System
2022
Tisch Cancer Institute
2020-2021
Mount Sinai Hospital
2021
Tisch Hospital
2021
Cancer Institute (WIA)
2021
Mount Sinai Hospital
2020
The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset patients, most patients do not respond. Tumors have adopted PD-1/PD-L1 axis escape to facilitate growth, which can be leveraged as potential target inhibitors. On this basis, PD-L1 protein expression on or cells emerged first predictive biomarker sensitivity blockade. goal our study was evaluate based...
Translational studies have shown that
Abstract Background Treatment options for penile squamous cell carcinoma are limited. We sought to investigate clinical outcomes and safety profiles of patients with receiving immune checkpoint inhibitors. Methods This retrospective study included locally advanced or metastatic inhibitors between 2015 2022 across 24 centers in the United States, Europe, Asia. Overall survival progression-free were estimated using Kaplan-Meier method. Objective response rates determined per Response...
Abstract Background Patients with malignancy are particularly vulnerable to infection Severe Acute Respiratory Disease‐Coronavirus‐2 (SARS‐CoV‐2) given their immunodeficiency secondary underlying disease and cancer‐directed therapy. We report a case series of patients cancer who received convalescent plasma, an investigational therapy for severe Coronavirus Disease 2019 (COVID‐19). Methods were identified plasma. Enrolled had confirmed COVID‐19 or life‐threatening transfused plasma from...
PURPOSE Outcomes data for DNA-damaging therapeutics men with prostate cancer (PC) and non- BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in PC treated poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS Retrospective from the PROMISE consortium were used. Clinical differences assessed between patients BRCA1/ 2 (cohort A) those without direct BRCA complex interaction B: ATM, CDK12, CHEK1, CHEK2,...
Abstract Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...
Prostate cancer exists in a clinical continuum of hormone-sensitive to castration-resistant disease. Despite the use chemotherapy and androgen synthesis inhibitors setting, this remains lethal The advent immune checkpoint blockade has changed outlook for treatment survival several tumors since its first approval 2011; however, benefit prostate (CRPC) is rather limited. Currently, Sipuleucel-T only modality be approved CRPC setting. Such resistance likely due low immunogenicity tumor cells an...
Response to immune checkpoint inhibitor (ICI) remains limited a subset of patients and predictive biomarkers response an unmet need, limiting our ability provide precision medicine. Using real-world data, we aimed identify potential clinical prognosticators ICI in solid tumor patients.We conducted retrospective analysis all treated with ICIs at the Mount Sinai Hospital between January 2011 April 2017. Predictors assessed included demographics, performance status, co-morbidities, family...
Abstract Microenvironmental signals and epigenetic changes can instruct proliferative disseminated tumor cells to enter dormancy. The combination of Azacitidine (AZA) All-trans retinoid acid (ATRA) reprogram active prostate cancer (PCa) into a dormant state. Herein, we evaluated the safety clinical activity AZA + ATRA in patients (pts) with biochemically recurrent PCa. Eligible pts were those diagnosis PCa post-local therapy rising PSA (PSADT < 10 mo). Pts excluded if they had...
Abstract Background: Prostate cancer is the 2nd leading cause of cancer-related deaths among men in US. CREB binding protein (CBP) and paralog p300 are co-activators androgen receptor (AR) relevant to metastatic castration-resistant prostate (mCRPC) progression AR therapy resistance. FT-7051 an oral, potent selective inhibitor CBP/p300 bromodomain with activity preclinical models, including those resistant enzalutamide. Methods: The Courage Study (NCT04575766) a first-in-human, multicenter,...